 | This articlerelies largely or entirely on asingle source. Relevant discussion may be found on thetalk page. Please helpimprove this article byintroducing citations to additional sources. Find sources: "Diproqualone" – news ·newspapers ·books ·scholar ·JSTOR(January 2025) |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.048.240 |
| Chemical and physical data | |
| Formula | C12H14N2O3 |
| Molar mass | 234.255 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Diproqualone is aquinazolinone classGABAergic and is an analogue ofmethaqualone developed in the late 1950s by a team at Nogentaise de Produits Chimique. It was marketed primarily in France and some other European countries.[1] It hassedative,anxiolytic,antihistamine andanalgesic properties, resulting from its agonist activity at the β subtype of theGABAa receptor, antagonist activity at allhistamine receptors, inhibition of thecyclooxygenase-1 enzyme, and possibly its agonist activity at both thesigma-1 receptor andsigma-2 receptor (the function of these receptors and their clinical relevance has not yet been determined). Diproqualone is used primarily for treating inflammatory pain associated with osteoarthritis and rheumatoid arthritis and more rarely, for treating insomnia, anxiety and neuralgia.
Diproqualone is the only analogue of methaqualone that is still in widespread clinical use, due to its useful anti-inflammatory and analgesic effects in addition to the sedative and anxiolytic actions common to other drugs of this class. There are still some concerns about the potential of diproqualone for abuse and overdose. So, it is not sold as a pure drug but only as the camphosulfonate salt in combination mixtures with other medicines such asethenzamide.
